INTRODUCTION: Erectile dysfunction (ED), as well as cardiovascular diseases (CVDs), is associated with endothelial dysfunction and increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha). AIM: We hypothesized that increased TNF-alpha levels impair cavernosal function. METHODS: In vitro organ bath studies were used to measure cavernosal reactivity in mice infused with vehicle or TNF-alpha (220 ng/kg/min) for 14 days. Gene expression of nitric oxide synthase isoforms was evaluated by real-time polymerase chain reaction. MAIN OUTCOME MEASURES: Corpora cavernosa from TNF-alpha-infused mice exhibited decreased nitric oxide (NO)-dependent relaxation, which was associated with decreased endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) cavernosal expression. RESULTS: Cavernosal strips from the TNF-alpha-infused mice displayed decreased nonadrenergic-noncholinergic (NANC)-induced relaxation (59.4 +/- 6.2 vs. control: 76.2 +/- 4.7; 16 Hz) compared with the control animals. These responses were associated with decreased gene expression of eNOS and nNOS (P < 0.05). Sympathetic-mediated, as well as phenylephrine (PE)-induced, contractile responses (PE-induced contraction; 1.32 +/- 0.06 vs. control: 0.9 +/- 0.09, mN) were increased in cavernosal strips from TNF-alpha-infused mice. Additionally, infusion of TNF-alpha increased cavernosal responses to endothelin-1 and endothelin receptor A subtype (ET(A)) receptor expression (P < 0.05) and slightly decreased tumor necrosis factor-alpha receptor 1 (TNFR1) expression (P = 0.063). CONCLUSION: Corpora cavernosa from TNF-alpha-infused mice display increased contractile responses and decreased NANC nerve-mediated relaxation associated with decreased eNOS and nNOS gene expression. These changes may trigger ED and indicate that TNF-alpha plays a detrimental role in erectile function. Blockade of TNF-alpha actions may represent an alternative therapeutic approach for ED, especially in pathologic conditions associated with increased levels of this cytokine.
INTRODUCTION:Erectile dysfunction (ED), as well as cardiovascular diseases (CVDs), is associated with endothelial dysfunction and increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha). AIM: We hypothesized that increased TNF-alpha levels impair cavernosal function. METHODS: In vitro organ bath studies were used to measure cavernosal reactivity in mice infused with vehicle or TNF-alpha (220 ng/kg/min) for 14 days. Gene expression of nitric oxide synthase isoforms was evaluated by real-time polymerase chain reaction. MAIN OUTCOME MEASURES: Corpora cavernosa from TNF-alpha-infused mice exhibited decreased nitric oxide (NO)-dependent relaxation, which was associated with decreased endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) cavernosal expression. RESULTS: Cavernosal strips from the TNF-alpha-infused mice displayed decreased nonadrenergic-noncholinergic (NANC)-induced relaxation (59.4 +/- 6.2 vs. control: 76.2 +/- 4.7; 16 Hz) compared with the control animals. These responses were associated with decreased gene expression of eNOS and nNOS (P < 0.05). Sympathetic-mediated, as well as phenylephrine (PE)-induced, contractile responses (PE-induced contraction; 1.32 +/- 0.06 vs. control: 0.9 +/- 0.09, mN) were increased in cavernosal strips from TNF-alpha-infused mice. Additionally, infusion of TNF-alpha increased cavernosal responses to endothelin-1 and endothelin receptor A subtype (ET(A)) receptor expression (P < 0.05) and slightly decreased tumor necrosis factor-alpha receptor 1 (TNFR1) expression (P = 0.063). CONCLUSION: Corpora cavernosa from TNF-alpha-infused mice display increased contractile responses and decreased NANC nerve-mediated relaxation associated with decreased eNOS and nNOS gene expression. These changes may trigger ED and indicate that TNF-alpha plays a detrimental role in erectile function. Blockade of TNF-alpha actions may represent an alternative therapeutic approach for ED, especially in pathologic conditions associated with increased levels of this cytokine.
Authors: T Holm; P Aukrust; A K Andreassen; T Ueland; F Brosstad; S S Frøland; S Simonsen; L Gullestad Journal: Clin Transplant Date: 2000-06 Impact factor: 2.863
Authors: F Giugliano; K Esposito; C Di Palo; M Ciotola; G Giugliano; R Marfella; M D'Armiento; D Giugliano Journal: J Endocrinol Invest Date: 2004 Jul-Aug Impact factor: 4.256
Authors: Barbara T Alexander; Kathy L Cockrell; Matthew B Massey; William A Bennett; Joey P Granger Journal: Am J Hypertens Date: 2002-02 Impact factor: 2.689
Authors: Stanley Chia; Motaz Qadan; Richard Newton; Christopher A Ludlam; Keith A A Fox; David E Newby Journal: Arterioscler Thromb Vasc Biol Date: 2003-03-06 Impact factor: 8.311
Authors: Giovanni Corona; Edoardo Mannucci; Alessandra D Fisher; Francesco Lotti; Luisa Petrone; Giancarlo Balercia; Elisa Bandini; Gianni Forti; Mario Maggi Journal: J Sex Med Date: 2008-05-20 Impact factor: 3.802
Authors: Jena B Giardina; Gachavis M Green; Kathy L Cockrell; Joey P Granger; Raouf A Khalil Journal: Am J Physiol Regul Integr Comp Physiol Date: 2002-07 Impact factor: 3.619
Authors: Josephine Hidalgo-Tamola; Ian Luttrell; Xiaogang Jiang; Dean Li; Robert P Mecham; Kanchan Chitaley Journal: J Sex Med Date: 2011-08-30 Impact factor: 3.802
Authors: Fernanda Priviero; Fabiano Calmasini; Vanessa Dela Justina; Camilla F Wenceslau; Cameron G McCarthy; R Clinton Webb Journal: J Sex Med Date: 2021-03-16 Impact factor: 3.802